Background
Methods
Cell lines and reagents
Human tissue samples
Clinical features | Values (number (%)) |
---|---|
Age(yr) | 51.3 ± 7.4 |
Gender | |
Male | 20 (76.92%) |
Female | 6 (23.08%) |
Aetiology | |
Hbs-Ag positive | 23 (88.46%) |
HCV-Ab positive | 3 (11.54%) |
Child-Pugh score | |
Class A | 26 (100%) |
Class B | 0 (0%) |
Tumour size | |
< 3 cm | 19 (73.07%) |
3-5 cm | 7 (26.93%) |
Tumour number | |
Single | 16 (61.53%) |
2–3 | 11 (38.47%) |
BCLC staging | |
Stage A | 18 (69.23%) |
Stage B | 8 (30.77%) |
Tumour differentiation | |
well | 9 (34.61%) |
moderate | 10 (38.46%) |
poorly | 7 (26.92%) |
AFP | 545 ± 892 |
CD-DST
Compounds | Concentration | ||||
---|---|---|---|---|---|
μg/ml | |||||
5-PU | 0.10 | 0.50 | 1.00 | 2.00 | 5.00 |
PAC | 0.01 | 0.02 | 0.05 | 0.08 | 0.10 |
CDDP | 0.10 | 0.20 | 0.50 | 1.00 | 2.00 |
EPI | 0.01 | 0.05 | 0.10 | 0.50 | 1.00 |
L-OHP | 0.10 | 0..50 | 1.00 | 2.00 | 5.00 |
Statistical analyses
Results
HepG2 cell cultures in collagen gel droplets
Test Batch | Baseline (0-time) | Solvent Control (6 days) | Growth rate (GR) |
---|---|---|---|
O.D. 540 nm | |||
1 | 22.18 | 97.95 | 4.1 |
25.45 | 92.33 | ||
22.11 | 95.47 | ||
2 | 26.29 | 108.51 | 4.56 |
23.48 | 95.29 | ||
18.21 | 106.31 | ||
3 | 19.83 | 111.03 | 4.62 |
23.21 | 114.15 | ||
29.61 | 110.76 |
HepG2 cells are sensitive to anti-tumor agents
Sensitivity of primary cells separated from HCC clinical specimens
Compounds | Total patients | Patients were sensitive to compounds | |
---|---|---|---|
IC
max
group |
IC
50
group | ||
5-FU | 26 | – | – |
PAC | 26 | – | – |
CDDP | 26 | 8 | 3 |
EPI | 26 | 9 | 4 |
L-OHP | 26 | 5 | 2 |
Compounds | Sensitive patients | BCLC | Child-Pugh | Tumor Number | Tumor differentiation | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
A | B | A | B | Single | 2~3 | Well | moderate | poorly | |||
CDDP |
IC
max
| 8 | 6 | 2 | 8 | – | 5 | 3 | 7 | 1 | – |
IC
50
| 3 | 3 | – | 3 | – | 2 | 1 | 3 | – | – | |
EPI |
IC
max
| 9 | 5 | 4 | 9 | – | 6 | 3 | 4 | 5 | – |
IC
50
| 4 | 3 | 1 | 4 | – | 2 | 2 | 2 | 2 | – | |
L-OHP |
IC
max
| 5 | 5 | – | 5 | – | 3 | 2 | 5 | 1 | – |
IC
50
| 2 | 2 | – | 2 | – | 1 | 1 | 2 | – | – | |
5-FU |
IC
max
| – | – | – | – | – | – | – | – | – | – |
IC
50
| – | – | – | – | – | – | – | – | – | – | |
PAC |
IC
max
| – | – | – | – | – | – | – | – | – | – |
IC
50
| – | – | – | – | – | – | – | – | – | – |
2-D cultured HepG2 cells were more sensitive to anti-tumor agents
Compounds | 2-D HepG2 | 2-D HepG2/ADR | 3-D HepG2 |
---|---|---|---|
IC
50
values (μg/ml) | |||
5-PU | 0.45 ± 0.06 | 0.77 ± 0.33 | 0.83 ± 0.45 |
PAC | 0.01 ± 0.00 | 0.02 ± 0.01 | 0.03 ± 0.02 |
CDDP | 0.26 ± 0.23 | 1.39 ± 0.40 | 1.15 ± 0.75 |
EPI | 0.02 ± 0.01 | 0.16 ± 0.04 | 0.09 ± 0.03 |
L-OHP | 0.55 ± 0.12 | 1.85 ± 0.44 | 1.76 ± 0.44 |